info@p-95.com

Clinical Trial Delivery

Comprehensive Clinical Trial Support for Vaccines and Infectious Disease.

Data, Analysis and writing

Our data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development.

Epidemiology and Real-World Evidence (RWE) Solutions

Comprehensive Epidemiology and RWE solutions for Vaccines and Infectious Diseases.

Africa and LMICs

Expanding Clinical and Epidemiological Horizons: Expertise in Africa, LMICs, and Beyond.

VIEW ALL SERVICES

about us

Want to Know a little more About us? Let us tell you.

P95 pioneers a positive impact on global health through specialized expertise in vaccines and infectious diseases and a broad clinical research and epidemiology offering that spans all stages of development, pre- and post-marketing.

Our History

We are driven to make a  difference to global health

P95 is a leading global provider of comprehensive clinical trial services, epidemiology, and real-world evidence (RWE) solutions, with a specialized focus on vaccine development and infectious diseases. We are:

N

founded in 2011

N

more than 300 staff

N

headquartered in belgium, operating on 5 continents

N

providing tailored clinical research across 30 countries

trusted by global organizations

Client logos

our locations

We are headquartered in Belgium, with regional hubs on 5 continents, and offices in Austria, Colombia, Ghana, France, Kenya, Morocco, The Netherlands, South Africa, Thailand, and the USA. Our international team is based across over 30 countries.

our history

 

Learn more about our history and 25+ years of combined experience.

2011

  • Foundation year, providing specialized consultancy services in pharmacovigilance and epidemiology, Leuven, Belgium

2015

  • Established a data analytics center

2021

  • Reacting to the challenges of the COVID-19 pandemic, P95 grew and expanded to new regions
  • Acquired Pallas (Netherlands)
  • First non-EU office (Colombia)

2023

  • Became an Ampersand portfolio company
  • First office in SE Asia (Thailand)
  • Acquired OnQ Research enhancing portfolio with valuable clinical trial experience (South Africa)

2024